Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Intensity Therapeutics, Inc. ( (INTS) ) has issued an update.
On March 23, 2026, Intensity Therapeutics, Inc. increased the capacity of its existing at-the-market equity offering program to $60 million, expanding the amount of common stock it may issue under an agreement with H.C. Wainwright & Co. LLC. The company emphasized it is not obligated to sell any shares and that any use of the facility will depend on market conditions, demand for its stock and strategic priorities, aiming to enhance financial flexibility without guaranteeing future placements.
The most recent analyst rating on (INTS) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.
Spark’s Take on INTS Stock
According to Spark, TipRanks’ AI Analyst, INTS is a Neutral.
The score is primarily constrained by weak financial performance (no meaningful revenue, ongoing losses, and material cash burn indicating continued reliance on external funding). Technicals also weigh on the score with bearish trend signals (below short-term moving averages and negative MACD). Valuation is neutral-to-weak because a negative P/E limits comparability and there is no dividend yield support.
To see Spark’s full report on INTS stock, click here.
More about Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing cancer therapies and accesses capital markets to support its operations, including through at-the-market equity offering programs that provide flexible financing capacity tied to its common stock.
Average Trading Volume: 56,993
Technical Sentiment Signal: Sell
Current Market Cap: $15.15M
For detailed information about INTS stock, go to TipRanks’ Stock Analysis page.